Literature DB >> 9418970

Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice.

S Forss-Petter1, H Werner, J Berger, H Lassmann, B Molzer, M H Schwab, H Bernheimer, F Zimmermann, K A Nave.   

Abstract

In its severe form, X-linked adrenoleukodystrophy (ALD) is a lethal neurologic disease of children, characterized by progressive cerebral demyelination and adrenal insufficiency. Associated with a biochemical defect of peroxisomal beta-oxidation, very long-chain fatty acids (VLCFA) build up in tissues that have a high turnover of lipids, such as central nervous system (CNS) white matter, adrenal cortex, and testis. Whether the abnormal accumulation of VLCFA is the underlying cause of demyelination or merely an associated biochemical marker is unknown. ALD is caused by mutations in the gene for a peroxisomal membrane protein (ALDP) that shares structural features with ATP-binding-cassette (ABC) transporters. To analyze the cellular function of ALDP and to obtain an animal model of this debilitating disease, we have generated transgenic mice with a targeted inactivation of the ald gene. Motor functions in ALDP-deficient mice developed at schedule, and unexpectedly, adult animals appeared unaffected by neurologic symptoms up to at least 6 months of age. Biochemical analyses demonstrated impaired beta-oxidation in mutant fibroblasts and abnormal accumulation of VLCFAs in the CNS and kidney. In 6-month-old mutants, adrenal cortex cells displayed a ballooned morphology and needle-like lipid inclusions, also found in testis and ovaries. However, lipid inclusions and demyelinating lesions in the CNS were not a feature. Thus, complete absence of ALDP expression results in a VLCFA storage disease but does not impair CNS function of young adult mice by pathologic and clinical criteria. This suggests that additional genetic or environmental conditions must be fulfilled to model the early-onset and lethality of cerebral ALD in transgenic mice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9418970     DOI: 10.1002/(SICI)1097-4547(19971201)50:5<829::AID-JNR19>3.0.CO;2-W

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  49 in total

1.  ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.

Authors:  Mauhamad Baarine; Craig Beeson; Avtar Singh; Inderjit Singh
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

Review 2.  On the front of X-linked adrenoleukodystrophy.

Authors:  P Aubourg
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

Review 3.  Evaluation of therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser; Ali Fatemi; Kathleen Zackowski; Seth Smith; Xavier Golay; Larry Muenz; Gerald Raymond
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

Review 4.  Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy.

Authors:  Johannes Berger; Aurora Pujol; Patrick Aubourg; Sonja Forss-Petter
Journal:  Brain Pathol       Date:  2010-07       Impact factor: 6.508

Review 5.  Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis.

Authors:  Inderjit Singh; Aurora Pujol
Journal:  Brain Pathol       Date:  2010-07       Impact factor: 6.508

6.  Activation of sirtuin 1 as therapy for the peroxisomal disease adrenoleukodystrophy.

Authors:  L Morató; M Ruiz; J Boada; N Y Calingasan; J Galino; C Guilera; M Jové; A Naudí; I Ferrer; R Pamplona; M Serrano; M Portero-Otín; M F Beal; S Fourcade; A Pujol
Journal:  Cell Death Differ       Date:  2015-03-27       Impact factor: 15.828

7.  A zebrafish model of X-linked adrenoleukodystrophy recapitulates key disease features and demonstrates a developmental requirement for abcd1 in oligodendrocyte patterning and myelination.

Authors:  Lauren R Strachan; Tamara J Stevenson; Briana Freshner; Matthew D Keefe; D Miranda Bowles; Joshua L Bonkowsky
Journal:  Hum Mol Genet       Date:  2017-09-15       Impact factor: 6.150

8.  Pharmacological Complementation Remedies an Inborn Error of Lipid Metabolism.

Authors:  Meredith D Hartley; Mitra D Shokat; Margaret J DeBell; Tania Banerji; Lisa L Kirkemo; Thomas S Scanlan
Journal:  Cell Chem Biol       Date:  2020-03-12       Impact factor: 8.116

9.  Murine bubblegum orthologue is a microsomal very long-chain acyl-CoA synthetase.

Authors:  Peter Fraisl; Sonja Forss-Petter; Mihaela Zigman; Johannes Berger
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

10.  Metabolic rerouting via SCD1 induction impacts X-linked adrenoleukodystrophy.

Authors:  Quentin Raas; Malu-Clair van de Beek; Sonja Forss-Petter; Inge Me Dijkstra; Abigail Deschiffart; Briana C Freshner; Tamara J Stevenson; Yorrick Rj Jaspers; Liselotte Nagtzaam; Ronald Ja Wanders; Michel van Weeghel; Joo-Yeon Engelen-Lee; Marc Engelen; Florian Eichler; Johannes Berger; Joshua L Bonkowsky; Stephan Kemp
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.